MannKind (MNKD) vs. CytomX Therapeutics (CTMX) Head-To-Head Analysis

MannKind (NASDAQ: MNKD) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MannKind and CytomX Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MannKind 2 1 1 0 1.75
CytomX Therapeutics 1 2 8 0 2.64

MannKind currently has a consensus price target of $0.92, suggesting a potential downside of 63.25%. CytomX Therapeutics has a consensus price target of $33.88, suggesting a potential upside of 32.58%. Given CytomX Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than MannKind.

Volatility & Risk

MannKind has a beta of 3.08, suggesting that its share price is 208% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Valuation and Earnings

This table compares MannKind and CytomX Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MannKind $174.76 million 1.69 $125.66 million ($0.27) -9.22
CytomX Therapeutics $15.04 million 65.25 -$58.90 million ($1.59) -16.07

MannKind has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.1% of MannKind shares are held by institutional investors. Comparatively, 63.1% of CytomX Therapeutics shares are held by institutional investors. 1.1% of MannKind shares are held by insiders. Comparatively, 8.0% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


This table compares MannKind and CytomX Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MannKind -155.83% -24.93% -130.34%
CytomX Therapeutics -113.64% -92.42% -20.70%


CytomX Therapeutics beats MannKind on 8 of the 14 factors compared between the two stocks.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit